Clinical Trial Update: Oral Fosamprenavir + Sodium Alginate for GERD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of fosamprenavir and sodium alginate for gastroesophageal reflux disease, with status not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Fosamprenavir (fosamprenavir)
• Sodium alginate (sodium alginate)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease | Phase 2 | Status: NOT_YET_RECRUITING